Molecule Details
InChIKeyNUZWLKWWNNJHPT-UHFFFAOYSA-N
Canonical SMILESO=C1c2c(O)cccc2Cc2cccc(O)c21
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)2
Pfam Stratification Cross-Family
Avg pChEMBL6.82
SourceChEMBL;BindingDB
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB11157
Drug NameAnthralin
CAS Number1143-38-0
Groups approved
ATC Codes D05AC01 D05AC51
DescriptionAnthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. Adverse effects of anthralin include irritation and discoloration of the skin [A27277]. This specifi...

Categories: Anthracenes Antipsoriatics Antipsoriatics for Topical Use Antracen Derivatives Dermatologicals
Cross-references: BindingDB: 50041802 ChEBI: 37510 CHEMBL46469 ChemSpider: 2117 Drugs Product Database (DPD): 9362 C06831 PubChem:2202 PubChem:347827926 RxCUI: 873 Wikipedia: Dithranol ZINC: ZINC000000001322
Target Activities (2)
Target Gene Organism Category Pfam pChEMBL Type Source
Q9NXA8 SIRT5 Homo sapiens Human PF02146 7.0 IC50 ChEMBL;BindingDB
P05981 HPN Homo sapiens Human PF09272 PF00089 6.6 IC50 ChEMBL;BindingDB
DrugBank Target Actions (3)
Target Gene Target Name Action Type
Q9UQF2 Q9UQF2 C-Jun-amino-terminal kinase-interacting protein 1 agonist targets
P35908 P35908 Keratin, type II cytoskeletal 2 epidermal antagonist targets
Q99456 Q99456 Keratin, type I cytoskeletal 12 antagonist targets